Formaldehyde

Formaldehyde

SCHEMBL3301090

C=O.Nc1nc(N)nc(N)n1.Nc1nc(N)nc(N)n1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
CASP1 P29466 1/20 0.42
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALOX15 P16050 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formaldehyde SCHEMBL20816 1.00 LMNA (0.45) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL6550879 1.00 LMNA (0.45) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL7797548 1.00 LMNA (0.45) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL11786670 1.00 LMNA (0.45) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL9861640 1.00 LMNA (0.45) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL2452911 0.96 LMNA (0.43) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL11376350 0.96 LMNA (0.43) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL21633883 0.96 LMNA (0.43) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL11756827 0.96 LMNA (0.43) LMNACASP1CYP1A2POLBADORA3
Formaldehyde SCHEMBL9840587 0.96 LMNA (0.43) LMNACASP1CYP1A2POLBADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3453751-A1 USE OF GLYCERIN SHORT-CHAIN ALIPHATIC ETHER COMPOUNDS Ecolab USA Inc. (US) 2019-03-13 EP disclosed
EP-2024455-B1 HIGHLY PRODUCTIVE COATING COMPOSITION FOR AUTOMOTIVE REFINISHING COATINGS FOREIGN IP CO LLC (US) 2018-04-04 EP disclosed
EP-3256318-A1 HOT-MELT, CURL-FREE COMPOSITIONS, STRUCTURES AND METHODS Jindal Films Americas LLC (US) 2017-12-20 EP disclosed
WO-2016131054-A1 HOT-MELT, CURL-FREE COMPOSITIONS, STRUCTURES AND METHODS JINDAL FILMS AMERICAS LLC (US) 2016-08-18 WO disclosed
US-8901056-B2 Reducing viscosity utilizing glycerin short-chain aliphatic ether compounds ECOLAB USA INC. (US) 2014-12-02 US disclosed
US-20120309849-A1 USE OF GLYCERIN SHORT-CHAIN ALIPHATIC ETHER COMPOUNDS ECOLAB USA INC. 2012-12-06 US disclosed
US-7737243-B2 Highly productive coating composition for automotive refinishing E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-06-15 US disclosed
US-7629394-B2 UV curable coating material of encapsulated water dispersed core material APPLETON PAPERS INC. (US) 2009-12-08 US disclosed
EP-2024455-A2 HIGHLY PRODUCTIVE COATING COMPOSITION FOR AUTOMOTIVE REFINISHING E.I. DU PONT DE NEMOURS AND COMPANY (US) 2009-02-18 EP disclosed
EP-2018402-A2 ULTRAPRODUCTIVE COATING COMPOSITION USING A CHEMICALLY MIXED ISOCYANATE SYSTEM E.I. DU PONT DE NEMOURS AND COMPANY (US) 2009-01-28 EP disclosed
EP-1446435-A1 PREPARATION AND USE OF BIURET-CONTAINING POLYISOCYANATES AS CROSS-LINKING AGENTS FOR COATINGS Bayer Aktiengesellschaft (DE) 2004-08-18 EP disclosed
EP-1353999-A2 COMPOSITIONS FOR PRINTABLE MEDIA AVERY DENNISON CORPORATION (US) 2003-10-22 EP disclosed
US-20030109664-A1 Preparation and use of biuret-containing polyisocyanates as cross-linking agents for coatings BAYER POLYMERS LLC 2003-06-12 US disclosed
US-6548189-B1 Epoxidized cashew nutshell liquid, a catalyst, and bisphenol a diglycidyl ether GENERAL ELECTRIC COMPANY 2003-04-15 US disclosed
WO-2003025040-A1 PREPARATION AND USE OF BIURET-CONTAINING POLYISOCYANATES AS CROSS-LINKING AGENTS FOR COATINGS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-03-27 WO disclosed
EP-1027007-A4 DENTAL TREATMENT METHODS LYTINAS MICHAIL (US) 2002-10-23 EP disclosed
WO-2002048260-A2 COMPOSITIONS FOR PRINTABLE MEDIA AVERY DENNISON CORPORATION (US) 2002-06-20 WO disclosed
EP-1027007-A1 DENTAL TREATMENT METHODS Lytinas, Michail (US) 2000-08-16 EP disclosed
WO-2000009030-A1 DENTAL TREATMENT METHODS LYTINAS MICHAIL (US) 2000-02-24 WO disclosed
US-4772669-A ELECTRODEPOSITABLE EPOXY RESIN OR POLYEPOXIDE-PROTECTIVE COATING INTERIOR FOOD CONTAINERS SHELL OIL COMPANY (US) 1988-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309849-A1 USE OF GLYCERIN SHORT-CHAIN ALIPHATIC ETHER COMPOUNDS GK, PHOSPHO1, UGCG LMNA 570/4885CASP1 4229/4885CYP1A2 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.